ReviewPharmacology & therapeutics2012
Integrins as receptor targets for neurological disorders.
Review in Pharmacology & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.
- Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO.Functional & integrative genomics · 2025Pooled it
- Blocking the mCellular & molecular immunology · 2026Article
- The potential and therapeutic advances of the integrin family in neurological disorders.Neural regeneration research · 2026Article
- Integrin α5β1 Activation by PHSRN Peptide Elicits Neuroprotection and Functional Recovery in Parkinson's Disease Mice.Antioxidants (Basel, Switzerland) · 2026Article
- Stochastic Nanoscale Biophysical Cues as a Basis for the Induction of Glioblastoma-Like Transcriptional Programs in Astrocytes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma.RSC advances · 2026Review
- The Crossroads of Neurodegeneration: Exploring the Overlap Between Alzheimer's Disease and Depression.Cureus · 2026Review
- Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.Pharmaceutics · 2026Review
- Altered Fibronectin-α5β1 Integrin-Src Signalling Pathway Drives Network Hyperexcitability in the Hippocampal Formation and Anterior Temporal Lobe in Temporal Lobe Epilepsy.Neurochemical research · 2026Article
- Temporal lobe epilepsy is associated with neuroinflammation, extracellular matrix remodeling, and synaptic protein alterations.Frontiers in molecular neuroscience · 2026Article
- iRUNNER: A Baseline Mutation Burden Regression for Identifying Gene Interaction Between Rare Variants for Diseases.Genomics, proteomics & bioinformatics · 2025Article
- Distinct microRNA profiles in neuron-derived extracellular vesicles between recent-onset and chronic-phase schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Cell-generated mechanical forces play a role in epileptogenesis after injury.Experimental neurology · 2025Article
- Making tracks: microglia and the extracellular matrix.Molecular neurodegeneration · 2025Review
- Investigation of Anticonvulsant Potential ofInternational journal of molecular sciences · 2025Article
- Voltage-Gated Calcium Channels Play a Central Role in Caenorhabditis elegans Response to Noxious Heat.Neurochemical research · 2025Article
- Differential gene expression patterns in Niemann-Pick Type C and Tay-Sachs diseases: Implications for neurodegenerative mechanisms.PloS one · 2025Article
- The ketone body β-hydroxybutyrate ameliorates neurodevelopmental deficits in the GABAergic system ofeLife · 2024Article
- Connecting genomic and proteomic signatures of amyloid burden in the brain.medRxiv : the preprint server for health sciences · 2024Article
- Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms.Journal of neuroinflammation · 2024Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
This review focuses on the neurobiology of integrins, pathophysiological roles of integrins in neuroplasticity and nervous system disorders, and therapeutic implications of integrins as potential drug targets and possible delivery pathways. Neuroplasticity is a central phenomenon in many neurological conditions such as seizures, trauma, and traumatic brain injury. During the course of many brain diseases, in addition to intracellular compartment changes, alterations in non-cell compartments such as extracellular matrix (ECM) are recognized as an essential process in forming and reorganizing neural connections. Integrins are heterodimeric transmembrane receptors that mediate cell-ECM and cell-cell adhesion events. Although the mechanisms of neuroplasticity remain unclear, it has been suggested that integrins undergo plasticity including clustering through interactions with ECM proteins, modulating ion channels, intracellular Ca(2+) and protein kinase signaling, and reorganization of cytoskeletal filaments. As cell surface receptors, integrins are central to the pathophysiology of many brain diseases, such as epilepsy, and are potential targets for the development of new drugs for neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.